

# **Non-Clinical Scientist**

The Role: Syntis Bio is developing a novel drug delivery technology, SYNT, which is a mucoadhesive polymer formed in vivo in the gastrointestinal tract that can be utilized in multiple ways. Syntis Bio is seeking a scientist to lead pharmacology and mechanism of action studies for delivery of existing and novel therapeutics with SYNT for improved treatment of several therapeutic indications. This role will be essential in driving our preclinical strategy for the advancement of programs utilizing SYNT. In addition, the scientist will work with the regulatory, CMC, and clinical teams, as well as external partners. The role is on-site and located in Dorchester in Boston, MA.

## The Responsibilities:

- Lead nonclinical study planning and execution to develop our understanding of the mechanism of action of a novel drug delivery technology used with existing and novel therapeutics
- Identify and implement animal models to test performance of delivery of therapeutics with SYNT for a wide range of indications
- Develop a deep understanding of the barriers to drug absorption from the gastrointestinal tract for different therapeutics and how SYNT can be utilized to overcome these barriers
- Plan and execute in vitro, ex vivo, and in vivo studies to aid the development and optimization of SYNT formulations
- Support nonclinical sections of regulatory filings including INDs, BLAs, and NDAs
- Interpret, analyze, present, and properly record data.
- Support general lab maintenance and safety operations
- Prepare documents and presentations that encompass project progression.
- Perform job related duties as assigned.

#### The Ideal Skills:

- PhD in biology, pharmacology, or related discipline + a minimum of 1-3 years of industry experience or MS/BS with 5+ years of industry experience (level will be commensurate with experience).
- Experience with a wide range of animal models for a wide range of therapeutic agents
- Understanding of methods to evaluate ADME properties of a range of therapeutics for oral delivery
- Scientifically driven to overcome complex technical challenges that are impacted by multiple drug delivery factors
- Experience with nonclinical strategies to identify factors that may limit the oral bioavailability of molecules with low permeability (Ex. BCS Class III/IV, peptides)
- Strong record of deliberate mentorship or management of junior level staff.
- Proven ability to lead the scientific direction of a project.
- Strong written and oral communication skills for technical and non-technical audiences.



### **About Syntis Bio**

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA. For more information, please visit www.synts.bio and follow on Linkedin.

### Syntis Bio is pleased to offer:

- Medical, dental, and vision coverage options.
- Bonus and Equity Plan
- Flexible time off
- Commuter Transit Plan
- Flexible Spending Account Plan
- 401(k) retirement Plan
- Short-Term Disability (STD), Long-Term Disability (LTD), and Life Insurance Plans